



Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: David Polinsky
Cornerstone Pharmaceuticals, Inc.
(609) 409-7050 ext 202
news@cornerstonepharma.com

CORNERSTONE PHARMACEUTICALS ANNOUNCES PRESENTATIONS REGARDING ITS PROPRIETARY ANTICANCER COMPOUND CPI-613 AT 2012 ANNUAL AACR MEETING

CRANBURY, NJ (April 02, 2012) Cornerstone Pharmaceuticals, Inc. (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, announces its poster presentations exhibited at the American Association for Cancer Research (AACR) 2012 Annual Meeting in Chicago, Illinois.

Cornerstone presented two posters at the 2012 AACR Annual Meeting dealing with its Altered Energy Metabolism Directed (AEMD) anticancer compounds. Details of each presentation are as follows:

Title: Lipoic acid analogs induce ROS, leading to potent mitochondrial enzyme inhibition, metabolic dysfunction and cell death in tumor cells

Presentation Date & Time: Monday, April 2, 2012, 8:00 AM -12:00 PM (Poster)

Abstract: #1122

A copy of the abstract of this poster presentation is available at:

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=317cc043-5335-4218-aacb-45093a1cce68&cKey=4ebf9ea2-8218-4a05-b85e-62faa5fb6c7c&mKey=%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d>

This poster, presenting research conducted in collaboration with Stony Brook University, summarizes results from a comprehensive metabolomic study indicating that AEMD compounds downregulate multiple mitochondria-associated enzymes associated with cancer energy metabolism. Furthermore, research reveals that reactive oxygen species (ROS) play a direct regulatory role in mitochondrial enzyme downregulation and is a major contributor to the resultant cancer-specific Krebs cycle inhibition and multiple cell death pathways observed after treatment of cancer cells with AEMD compounds.

Title: Regulation of pancreatic, gliosarcoma and non-small cell lung cancer via CPI-613, a novel anticancer therapeutic agent

Presentation Date & Time: Tuesday, April 3, 2012, 8:00 AM -12:00 PM (Poster)

Abstract: #3807

A copy of the abstract of this poster presentation is available at:

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=9013bd6c-690a-407b-89f4-db928ece0f2c&cKey=03de2272-ec75-4133-b70b-32a54192fcc9&mKey=%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d>



This poster discloses gene microarray data that demonstrates that CPI-613, the lead AEMD compound currently in human clinical trials, exerts *in vitro* cancer-cell-cycle-specific effects on various types of human cancer cells but not on non-transformed cells. Specific genes regulated by CPI-613 affect signal transduction pathways and genes related to cell cycle maintenance and progression as well as energetic metabolic processes and pathways, all of which halt the cell cycle at multiple points.

Dr. Robert Shorr, Chief Executive Officer of Cornerstone, commented "It is gratifying to see that our preclinical knowledge of the mechanism of action of CPI-613 is increasing. It is our hope that our preclinical research will continue to translate well in the clinic."

CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD drug platform. Cornerstone's AEMD compounds disrupt biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that control, among other things, cancer cell growth and development, as well as various forms of cell death, including apoptosis and necrosis. The platform is designed to produce drugs, such as the company's lead drug CPI-613, that disrupt energy-production pathways whose organization or regulation are altered specifically in cancer cells. CPI- 613 is currently being evaluated in a Phase 1 trial.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management, and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research, and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.

###

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.